Tara Baetz
YOU?
Author Swipe
View article: Invasive Melanoma Arising in a <scp>BAP1</scp>‐Inactivated Melanocytic Tumor With <i>NRAS</i> Mutation: A Report of Exceptional Case With Emphasis on Its Genomic Features and Review of the Literature
Invasive Melanoma Arising in a <span>BAP1</span>‐Inactivated Melanocytic Tumor With <i>NRAS</i> Mutation: A Report of Exceptional Case With Emphasis on Its Genomic Features and Review of the Literature Open
BAP1‐inactivated melanocytic tumor is a distinct entity with loss of BAP1 protein and epithelioid morphology. It shares histopathologic features with Spitz nevus and nevoid melanoma, and it can occur sporadically or with germline BAP1 pred…
View article: Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients
Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients Open
Our study suggested a high proportion of real-world patients would have been deemed non-eligible for clinical trials. Regardless, adjuvant systemic therapy delivered similar survival and toxicity outcomes in both groups.
View article: Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03 Open
Background We report extended follow-up of TROG99.03, a randomised phase III trial in early-stage follicular lymphoma (ESFL) including new information on the role of adjuvant rituximab and translational studies. Methods Patients with ESFL …
View article: Identification of genetic subtypes in follicular lymphoma
Identification of genetic subtypes in follicular lymphoma Open
Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes in 713 pre-trea…
View article: Single gene mutations and prognosis in limited‐stage follicular lymphoma treated with radiation therapy
Single gene mutations and prognosis in limited‐stage follicular lymphoma treated with radiation therapy Open
Summary Radiotherapy is routinely used for management of limited‐stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We performed targe…
View article: Canadian cancer trials group <scp>LY</scp>.17: A randomized phase <scp>II</scp> study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐<scp>DICEP</scp>) versus R‐<scp>GDP</scp>
Canadian cancer trials group <span>LY</span>.17: A randomized phase <span>II</span> study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐<span>DICEP</span>) versus R‐<span>GDP</span> Open
Summary The Canadian Cancer Trials Group (CCTG) LY.17 is an ongoing multi‐arm randomized phase II trial evaluating novel salvage therapies compared with R‐GDP (rituximab, gemcitabine, dexamethasone and cisplatin) in autologous stem cell tr…
View article: Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review
Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review Open
Surveillance protocols should be based on individual risk of recurrence and established best practices when formulating follow-up strategies, as suggested by the studies reviewed. Future high-quality studies are needed to clarify the frequ…
View article: Data from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome
Data from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome Open
Purpose: Follicular lymphoma, the most common indolent lymphoma, is clinically heterogeneous. CDKN2A encodes the tumor suppressors p16INK4a and p14ARF and frequently suffers deleterious alterations in cancer. We investigated the hypothesis…
View article: Supplementary Data 1 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
Supplementary Data 1 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs Open
Supplementary Data 1 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
View article: Supplementary Tables 1 - 4 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome
Supplementary Tables 1 - 4 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome Open
PDF file - 96K, Table S1: Sequences of primers used in SNP determination by Sequenom iPLEX assay. Table S2: Primers used for deletion analysis by end-point PCR. Table S3: Validation of MethylLight assay for quantification of CpG island met…
View article: Data from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
Data from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs Open
Purpose: Follicular lymphoma is a common lymphoma of adults. Although its course is often indolent, a substantial proportion of patients have a poor prognosis, often due to rapid progression or transformation to a more aggressive lymphoma.…
View article: Supplementary Figure 1 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome
Supplementary Figure 1 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome Open
PDF file - 68K, (A) Laser capture microdissection of neoplastic lymphoid follicles. A histological section immunostained for CD20 is shown before and (B) after laser capture microdissection of 4 neoplastic lymphoid follicles.
View article: Supplementary Figure 2 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome
Supplementary Figure 2 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome Open
PDF file - 62K, (A) Overall survival according to CDKN2A deletion status. (B) Overall survival according to CDKN2A methylation status.
View article: Data from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
Data from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs Open
Purpose: Follicular lymphoma is a common lymphoma of adults. Although its course is often indolent, a substantial proportion of patients have a poor prognosis, often due to rapid progression or transformation to a more aggressive lymphoma.…
View article: Supplementary Tables 1 - 4 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome
Supplementary Tables 1 - 4 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome Open
PDF file - 96K, Table S1: Sequences of primers used in SNP determination by Sequenom iPLEX assay. Table S2: Primers used for deletion analysis by end-point PCR. Table S3: Validation of MethylLight assay for quantification of CpG island met…
View article: Data from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome
Data from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome Open
Purpose: Follicular lymphoma, the most common indolent lymphoma, is clinically heterogeneous. CDKN2A encodes the tumor suppressors p16INK4a and p14ARF and frequently suffers deleterious alterations in cancer. We investigated the hypothesis…
View article: Supplementary Figure 2 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome
Supplementary Figure 2 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome Open
PDF file - 62K, (A) Overall survival according to CDKN2A deletion status. (B) Overall survival according to CDKN2A methylation status.
View article: Supplementary Data 2 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
Supplementary Data 2 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs Open
Supplementary Data 2 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
View article: Supplementary Figure 3 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome
Supplementary Figure 3 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome Open
PDF file - 49K, Overall survival according to pRb expression as determined by visual scoring of immunohistochemically stained slides.
View article: Supplementary Data 2 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
Supplementary Data 2 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs Open
Supplementary Data 2 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
View article: Supplementary Data 1 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
Supplementary Data 1 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs Open
Supplementary Data 1 from Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
View article: Supplementary Figure 3 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome
Supplementary Figure 3 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome Open
PDF file - 49K, Overall survival according to pRb expression as determined by visual scoring of immunohistochemically stained slides.
View article: Supplementary Figure 1 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome
Supplementary Figure 1 from Inactivation of the <i>CDKN2A</i> Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome Open
PDF file - 68K, (A) Laser capture microdissection of neoplastic lymphoid follicles. A histological section immunostained for CD20 is shown before and (B) after laser capture microdissection of 4 neoplastic lymphoid follicles.
View article: Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients Open
ICI therapy has greatly improved patient outcomes in melanoma, but at the cost of immune-related adverse events (irAEs). Data on the chronicity of irAEs, especially in real-world settings, are currently limited. We performed a retrospectiv…
View article: A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma
A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma Open
Background The 8 th edition UICC/AJCC TNM8 (Tumour, Nodes, Metastasis) melanoma staging system introduced several modifications from the 7 th edition (TNM7), resulting in changes in survival and subgroup composition. We set out to address …
View article: Improved Overall Survival in Dual Compared to Single Immune Checkpoint Inhibitors in <i>BRAF</i> V600-Negative Advanced Melanoma
Improved Overall Survival in Dual Compared to Single Immune Checkpoint Inhibitors in <i>BRAF</i> V600-Negative Advanced Melanoma Open
While limited by small sample size and retrospective nature, dual ICI may have non statistically significant trend toward better OS efficacy when compared with single ICI in BRAF V600 wild-type advanced melanoma patients.
View article: Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma
Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma Open
Aim: To evaluate optimal systemic therapy sequencing (first-line targeted therapy (1L-TT) vs. first-line immunotherapy (1L-IO)) in patients with BRAF-mutated metastatic melanoma. Methods: Nation-wide prospective data of patients with newly…
View article: Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events
Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events Open
Background: Immune-related adverse events (iRAEs) are known complications of immune checkpoint inhibitors (ICIs). Early identification and management leads to improved morbidity and mortality. This study seeks to address our center’s exper…
View article: Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016
Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016 Open
These findings suggest that innovations in systemic therapy and radiotherapy are associated with improvements in clinical outcomes among patients with melanoma brain metastasis, even in population-wide routine practice. Overall survival im…